Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 14/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.74 |
| ▸ | EGFR | P00533 | 3/20 | 0.74 |
| ▸ | KIT | P10721 | 2/20 | 0.74 |
| ▸ | NEK2 | P51955 | 2/20 | 0.74 |
| ▸ | MELK | Q14680 | 2/20 | 0.74 |
| ▸ | FLT3 | P36888 | 4/20 | 0.69 |
| ▸ | PRKAA1 | Q13131 | 14/20 | 0.68 |
| ▸ | PRKAA2 | P54646 | 13/20 | 0.68 |
| ▸ | PLK4 | O00444 | 2/20 | 0.65 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.65 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.65 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.65 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.65 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.65 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.65 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.65 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.65 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116563 | 1.00 | KDR (0.74) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL31672505 | 1.00 | KDR (0.74) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL144201 | 0.88 | KDR (0.74) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL2115618 | 0.87 | KDR (0.66) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL13755234 | 0.87 | KDR (0.66) | KDRPDGFRBFGFR1EGFRKIT | |
| SCHEMBL15202708 | 0.86 | KDR (0.79) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL21067494 | 0.86 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL2212420 | 0.86 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL2114096 | 0.86 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT | |
| Su-11652 SCHEMBL29366350 | 0.86 | KDR (1.00) | KDRPDGFRBFGFR1EGFRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | KYOTO UNIVERSITY (JP) | 2018-01-04 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572924-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320996-B2 | Indolinone protein kinase inhibitors and cyclooxygenase inhibitors for use in combination therapy for the treatment of cancer | SUGEN, INC (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2007-01-11 | — | — | US | disclosed |
| US-7125905-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. & PHARMACIA & UPJOHN CO. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176802-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, MAP3K20, PLK2 | KDR 1372/4885PDGFRB 974/4885FGFR1 1091/4885 |
| US-20180000771-A1 | AGENT FOR PREVENTING AND/OR TREATING AMYOTROPHIC LATERAL SCLEROSIS | WEE2, WEE1, ERBB2 | KDR 648/4885PDGFRB 40/4885FGFR1 48/4885 |
| US-20070010569-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | PDPK1, PLK2, PNCK | KDR 1387/4885PDGFRB 1034/4885FGFR1 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.